reviewTop 1% cited
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
European Journal of Cancer · 2012 · Vol. 48(16) · pp. 3082–3092
Allan Lipton✉(Penn State Milton S. Hershey Medical Center)Karim Fizazi(Université Paris-Sud)Alison Stopeck(University of Arizona)David H. Henry(Pennsylvania Hospital)Janet E. Brown(Cancer Research UK)Denise A. Yardley(Tennessee Oncology)Gary Richardson(Cabrini Hospital)Salvatore Siena(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda)Pablo Maroto(Hospital de Sant Pau)Michael Clemens(Klinikum Mutterhaus der Borromäerinnen)Boris BilynskyyVeena CharuPhilippe Beuzeboc(Institut Curie)Michael Rader(Nyack Hospital)María Eugenia Ibarrarán Viniegra(National University of General San Martín)Fred Saad(Université de Montréal)Chunlei Ke(Amgen (United States))Ada Braun(Amgen (United States))Susie Jun(Amgen (United States))
Bone health and treatmentsBone and Joint DiseasesBone Metabolism and DiseasesZoledronic acidDenosumabMedicineOncologyInternal medicineOsteoporosis
MeSH terms
DenosumabZoledronic AcidBone NeoplasmsDiphosphonatesFemaleHumansHypocalcemiaImidazolesMaleMiddle AgedRisk FactorsTime FactorsProportional Hazards ModelsSurvival AnalysisRandomized Controlled Trials as Topic
Funding
- Amgen
- Pfizer
Citations
583
FWCI
26.61
field-weighted impact
References
38
Percentile
100%
vs. same field & year
Citations per year
Cited by
American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update
Journal of Oral and Maxillofacial Surgery · 2014 · 2,869 citations
Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus
Journal of Bone and Mineral Research · 2014 · 1,324 citations
References
Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation
Cell · 1998 · 5,439 citations
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
Clinical Cancer Research · 2006 · 2,439 citations
Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis<i>in Vitro</i><sup>1</sup>
Endocrinology · 1998 · 1,206 citations
A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma
JNCI Journal of the National Cancer Institute · 2002 · 1,654 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.